Our preclinical assessment of the strategy showed that our HER2-VEGFA BsAbs exerted greater anti-metastasis activity against aggressive tumor models, leading to a greater survival benefit, than did the parental anti-HER2 and anti-VEGFA antibodies used alone or in simple combination. This evidence concerns the gene VEGFA and neoplasm.